Endosense (Switzerland), a commercial-stage medical device company focused on catheter ablation for cardiac arrhythmias, closed a $40.3M Series C financing. Participants included NGN Capital, Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.